The Swiss pharmaceutical company Roche reported that in the third quarter, it managed to increase sales by 7% to 13 billion 970 million Swiss francs due to an increase in revenue from the sale of new drugs, finversia.ru wrote. The indicator exceeded the forecasts of experts who had expected sales of 13,800 million francs. The company doubled its quarterly revenue from sales of Ocrevus, the drug for multiple sclerosis, compared to last year, and by 62% from sales of the anti-cancer drug Alecensa. Sales of another two new drugs – Perjeta, for the treatment of breast cancer, and the immunological drug Tecentriq – increased in annual terms by 27% and 71%, respectively.
